Stoke Therapeutics (STOK) Return on Sales (2022 - 2026)

Stoke Therapeutics has reported Return on Sales for 5 years, with the latest figure at 0.08% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 9.0% year-over-year to 0.08%; the trailing twelve-month figure through Mar 2026 stood at 0.05% (down 6.0% YoY), and the FY2025 full-year result was 0.0%, up 2.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.08%, up from 0.41% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q1 2025, with the low at 0.41% in Q4 2025.
• Average Return on Sales over 5 years is 0.08%, with a median of 0.07% recorded in 2023.
• Year-over-year, Return on Sales rose 9 bps in 2024 and sank 41 bps in 2025.
• Tracing STOK's Return on Sales over 5 years: stood at 0.08% in 2022, then decreased by 23 bps to 0.1% in 2023, then soared by 95 bps to 0.0% in 2024, then plunged by 8631 bps to 0.41% in 2025, then jumped by 81 bps to 0.08% in 2026.
• The last three Return on Sales figures came in at 0.08% (Q1 2026), 0.41% (Q4 2025), and 0.04% (Q3 2025), per Business Quant data.

Peer Comparison